Dosing concepts
How retatrutide dosing appears in clinical trials
A research-framed summary of how retatrutide has been dosed in published trials. Retatrutide is investigational and not available by prescription.
6 min read · Updated 2026-05-24
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
Why this is framed as ''in trials''
Retatrutide is not FDA-approved and is not available by prescription.
There is no established clinical dosing because there is no approved indication. The only structured dosing information that exists comes from the trial protocols themselves.
Trial design pattern
Phase 2 trials tested several once-weekly dose arms against placebo.
All arms began at a low introductory dose and escalated over a number of weeks before reaching the target arm dose.
Escalation was gradual for the same reason as other incretin drugs — to manage gastrointestinal side effects.
What the trials reported
Higher target dose arms showed larger average weight reduction at 48 weeks than lower arms.
Gastrointestinal side effects were the most common adverse events and were generally most pronounced during escalation.
Full trial-arm details are published in the New England Journal of Medicine and on ClinicalTrials.gov.
What this is not
These trial arms are not a dosing recommendation. They were administered under medical supervision, with monitoring, in a controlled study population.
Vials sold online as ''retatrutide'' are not the trial drug, are not verified for identity or purity, and are not legal to use as medicines.
If retatrutide becomes approved, official prescribing information will set actual clinical dosing — which may look very different from any single trial arm.
Key takeaways
- Retatrutide has no approved clinical dose because it is not approved.
- Published trial arms used gradual weekly escalation to a target dose.
- Trial-arm numbers are research data, not a prescription to self-administer.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.